5.23
2.88%
-0.155
After Hours:
5.23
Orasure Technologies Inc. stock is currently priced at $5.23, with a 24-hour trading volume of 860.31K.
It has seen a -2.88% decreased in the last 24 hours and a +0.19% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $5.39 pivot point. If it approaches the $5.23 support level, significant changes may occur.
Previous Close:
$5.385
Open:
$5.36
24h Volume:
860.31K
Market Cap:
$386.81M
Revenue:
$405.47M
Net Income/Loss:
$53.66M
P/E Ratio:
9.0172
EPS:
0.58
Net Cash Flow:
$131.28M
1W Performance:
+3.67%
1M Performance:
+0.19%
6M Performance:
-24.20%
1Y Performance:
-1.51%
Orasure Technologies Inc. Stock (OSUR) Company Profile
Name
Orasure Technologies Inc.
Sector
Industry
Phone
610-882-1820
Address
220 East First Street, Bethlehem, PA
Orasure Technologies Inc. Stock (OSUR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-03-23 | Resumed | Evercore ISI | In-line |
Sep-22-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
Aug-21-20 | Initiated | Evercore ISI | Outperform |
Aug-10-20 | Initiated | Citigroup | Buy |
Aug-10-20 | Initiated | JP Morgan | Neutral |
Aug-07-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jun-25-20 | Initiated | Lake Street | Buy |
Apr-21-20 | Resumed | Stephens | Equal-Weight |
Oct-23-18 | Resumed | Raymond James | Mkt Perform |
Jul-16-18 | Downgrade | Stephens | Overweight → Equal-Weight |
Nov-02-17 | Downgrade | Jefferies | Buy → Hold |
Feb-09-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jun-13-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-05-15 | Reiterated | Mizuho | Buy |
May-07-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Jan-23-15 | Reiterated | Mizuho | Buy |
Jun-12-14 | Reiterated | Canaccord Genuity | Buy |
Jun-11-14 | Reiterated | Mizuho | Buy |
Dec-21-12 | Initiated | Mizuho | Buy |
Aug-08-12 | Upgrade | Barrington Research | Mkt Perform → Outperform |
Jul-05-12 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Mar-27-12 | Initiated | JMP Securities | Mkt Outperform |
View All
Orasure Technologies Inc. Stock (OSUR) Latest News
Can you still get a good price for Orasure Technologies Inc. (OSUR) Shares at this point? – US Post News - US Post News
US Post News
OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Sold by Versor Investments LP - Defense World
Defense World
JPMorgan Chase & Co. Lowers OraSure Technologies (NASDAQ:OSUR) Price Target to $6.00 - Defense World
Defense World
Ready to Jump After Recent Trade: Orasure Technologies Inc. (OSUR) – Sete News - SETE News
SETE News
Orasure Technologies Inc. (OSUR) gets rating Resumed from Evercore ISI – Knox Daily - Knox Daily
Knox Daily
OraSure Technologies (NASDAQ:OSUR) Price Target Lowered to $6.00 at JPMorgan Chase & Co. - MarketBeat
MarketBeat
Orasure Technologies Inc. Stock (OSUR) Financials Data
Orasure Technologies Inc. (OSUR) Revenue 2024
OSUR reported a revenue (TTM) of $405.47 million for the quarter ending December 31, 2023, a +4.64% rise year-over-year.
Orasure Technologies Inc. (OSUR) Net Income 2024
OSUR net income (TTM) was $53.66 million for the quarter ending December 31, 2023, a +413.17% increase year-over-year.
Orasure Technologies Inc. (OSUR) Cash Flow 2024
OSUR recorded a free cash flow (TTM) of $131.28 million for the quarter ending December 31, 2023, a +218.15% increase year-over-year.
Orasure Technologies Inc. (OSUR) Earnings per Share 2024
OSUR earnings per share (TTM) was $0.72 for the quarter ending December 31, 2023, a +388.00% growth year-over-year.
About Orasure Technologies Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, OMNIgene DISCOVER, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, GenoFIND, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, retail pharmacies, mass merchandisers, and consumers. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.
Cap:
|
Volume (24h):